Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ME-401 × Other hematologic neoplasm × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Interventions

Cyclophosphamide 361 Cytarabine 297 fludarabine phosphate 200 Rituximab 187 fludarabine 168 Methotrexate 166 Azacitidine 159 venetoclax 153 Busulfan 144 Mycophenolic Acid 124 Whole-Body Irradiation 123 Filgrastim 123 Peripheral Blood Stem Cell Transplantation 119 Etoposide 117 Tacrolimus 113 Vincristine 97 Melphalan 95 Dexamethasone 95 Imatinib Mesylate 86 Cyclosporine 86 Granulocyte Colony-Stimulating Factor 79 Daunorubicin 78 Antilymphocyte Serum 78 Decitabine 77 Radiotherapy 76 Dasatinib 64 Lenalidomide 63 Doxorubicin 63 Idarubicin 59 Prednisone 58

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209308 2023-03-16

CORAL

MEI Pharma, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡